65岁以上活动性类风湿关节炎患者接受2年低剂量泼尼松龙附加治疗对体重和体成分的影响:随机双盲安慰剂对照GLORIA试验
GLORIA试验纳入451例65岁以上活动性类风湿关节炎患者,随机接受泼尼松龙5 mg/日或安慰剂附加标准治疗2年。本分析纳入449例,泼尼松龙组体重平均增加0.9 kg(95%CI 0.3至1.6),安慰剂组为-0.4 kg(95%CI -1.1至0.2),差值为1.3 kg(95%CI 0.5至2.2,p<0.01)。57例患者双能X线吸收法显示,体重增加主要来自瘦体重,总脂肪量无显著增加,脂肪分布无向中心性转移。
要点
- 泼尼松龙5 mg/日治疗2年,体重平均增加0.9 kg,安慰剂组为-0.4 kg,差值1.3 kg(p<0.01)。
- 体重增加独立于疾病活动度抑制,主要来自四肢瘦体重增加。
- 总脂肪量无显著增加,脂肪无外周向中心再分布。
核心结论
- 65岁以上活动性类风湿关节炎患者接受泼尼松龙5 mg/日治疗2年,体重增加约1 kg,而安慰剂组为轻微非显著体重下降。
- 数据提示体重的小幅增加主要是瘦体重,而非传统认为的糖皮质激素相关脂肪量增加或再分布。
研究设计与样本
- GLORIA试验为实用性、安慰剂对照、双盲、随机对照试验,评估泼尼松龙5 mg/日附加标准治疗2年的获益与风险平衡,共纳入451例65岁以上活动性类风湿关节炎患者。
- 本分析纳入449例患者,在基线及3、6、12、18、24个月测量体重和28关节疾病活动度评分。
- 57例患者在基线和2年后采用双能X线吸收法评估体成分。
- 数据分析采用纵向混合模型。
主要发现
- 泼尼松龙组体重平均变化为0.9 kg(95%CI 0.3至1.6),安慰剂组为-0.4 kg(95%CI -1.1至0.2),差值为1.3 kg(95%CI 0.5至2.2,p<0.01)。
- 治疗效应独立于疾病活动度抑制,且2年后体重增加主要来自(四肢)瘦体重增加。
- 总脂肪量无显著增加,脂肪量无外周向中心组织的再分布。
关键数值与推荐
- 泼尼松龙组体重平均变化0.9 kg(95%CI 0.3至1.6),安慰剂组-0.4 kg(95%CI -1.1至0.2),差值1.3 kg(95%CI 0.5至2.2,p<0.01)。
- 体成分在57例患者中于基线和2年后用双能X线吸收法评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the effect of 2 years of add-on prednisolone 5 mg/day on body weight and composition in patients with active rheumatoid arthritis (RA) aged 65+ and the relation with disease activity. METHODS: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis trial, a pragmatic, placebo-controlled, double-blind, randomised controlled trial investigated the balance of benefit and harm of 2 years of prednisolone 5 mg/day added to standard care in 451 patients with active RA aged 65+. In the current study, 449 patients were included, and body weight and Disease Activity Score of 28 Joints were measured at baseline and after 3, 6, 12, 18 and 24 months. In 57 patients, body composition was assessed at baseline and after 2 years with dual-energy X-ray absorptiometry. Data were analysed with longitudinal mixed models. RESULTS: The mean (95% CI) change in body weight was 0.9 (0.3 to 1.6) kg in the prednisolone group and -0.4 (-1.1 to 0.2) kg in the placebo group (difference 1.3 (0.5-2.2), (p<0.01)). The treatment effect was independent of disease activity suppression and comprised mostly increase in (appendicular) lean mass after 2 years. There was no significant increase in total fat mass, nor redistribution of fat mass from peripheral to central tissues. CONCLUSIONS: Patients with active RA aged 65+ treated with prednisolone 5 mg/day for 2 years gained about 1 kg in weight, compared with minimal-non-significant-weight loss on placebo. Our data suggest that the small increase in weight is mostly lean mass, rather than increase or redistribution of fat mass traditionally associated with glucocorticoid treatment.
引用
- Güler-Yüksel M, Kuijper M, Bos R, et al. Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial. RMD Open. 2023. PMID: 37349120. doi:10.1136/rmdopen-2022-002905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。